Payment overview · 2025
General Payments
$1,108.72
42 reported records · 12 companies
Healthcare provider profile · identity verified
Arun P Patel, MD
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · SALAMANCA, NY · NPI 1205815255
Verified facts
What the public records show
CMS Open Payments records show Arun P Patel, MD received $1,108.72 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Nuedexta, Ozempic, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $446.33 | 40.3% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $147.54 | 13.3% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $140.59 | 12.7% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $128.11 | 11.6% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.47 | 4.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.22 | 4.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.01 | 3.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.94 | 2.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.25 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.40 | 1.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.45 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.41 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,108.72 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $247.93 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $177.39 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $173.93 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $140.59 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $86.66 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.22 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.45 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.01 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 155 | exact normalized | Medicare Part D |
| NUEDEXTA nuedexta |
2025 | Nuedexta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
122 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1687 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1433 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1077 | 74 |
| Eliquis | Apixaban | 950 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 941 | 87 |
| Furosemide | Furosemide | 903 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 738 | 69 |
| Gabapentin | Gabapentin | 699 | 57 |
| Lisinopril | Lisinopril | 664 | 52 |
| Omeprazole | Omeprazole | 533 | 30 |
| Buspirone Hcl | Buspirone Hcl | 528 | 27 |
| Bumetanide | Bumetanide | 504 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 495 | 34 |
| Losartan Potassium | Losartan Potassium | 467 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 454 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 454 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 451 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 428 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 55 |
| Sertraline Hcl | Sertraline Hcl | 417 | 35 |
| Januvia | Sitagliptin Phosphate | 405 | 21 |
| Metformin Hcl | Metformin Hcl | 368 | 35 |
| Donepezil Hcl | Donepezil Hcl | 328 | 24 |
| Potassium Chloride | Potassium Chloride | 328 | 35 |
| Xarelto | Rivaroxaban | 315 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 287 | 37 |
| Memantine Hcl | Memantine Hcl | 279 | 18 |
| Trazodone Hcl | Trazodone Hcl | 272 | 15 |
| Montelukast Sodium | Montelukast Sodium | 234 | 23 |
| Divalproex Sodium | Divalproex Sodium | 228 | suppressed |
| Mirtazapine | Mirtazapine | 208 | 20 |
| Aripiprazole | Aripiprazole | 206 | 12 |
| Digoxin | Digoxin | 190 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 190 | 15 |
| Simvastatin | Simvastatin | 190 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 189 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 186 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 184 | suppressed |
| Risperidone | Risperidone | 178 | suppressed |
| Carvedilol | Carvedilol | 174 | 19 |
| Olanzapine | Olanzapine | 169 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 167 | 12 |
| Myrbetriq | Mirabegron | 160 | 11 |
| Warfarin Sodium | Warfarin Sodium | 158 | suppressed |
| Jardiance | Empagliflozin | 155 | 22 |
| Levetiracetam | Levetiracetam | 154 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 147 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 145 | suppressed |
| Finasteride | Finasteride | 131 | 11 |
| Prednisone | Prednisone | 131 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | suppressed |
| Spironolactone | Spironolactone | 127 | 13 |
| Allopurinol | Allopurinol | 123 | 15 |
| Entresto | Sacubitril/Valsartan | 122 | suppressed |
| Sucralfate | Sucralfate | 120 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 111 | 14 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 109 | suppressed |
| Topiramate | Topiramate | 107 | suppressed |
| Lorazepam | Lorazepam | 106 | 43 |
| Atenolol | Atenolol | 103 | 11 |
| Alendronate Sodium | Alendronate Sodium | 101 | 12 |
| Alprazolam | Alprazolam | 92 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 83 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 30 |
| Bupropion Xl | Bupropion Hcl | 74 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 72 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 67 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | suppressed |
| Torsemide | Torsemide | 67 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 66 | suppressed |
| Primidone | Primidone | 66 | suppressed |
| Acetazolamide | Acetazolamide | 64 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 63 | suppressed |
| Ranolazine Er | Ranolazine | 62 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 62 | 22 |
| Farxiga | Dapagliflozin Propanediol | 61 | suppressed |
| Irbesartan | Irbesartan | 61 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 21 |
| Galantamine Hbr | Galantamine Hbr | 58 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 57 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 56 | suppressed |
| Invokana | Canagliflozin | 53 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 53 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 52 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 11 |
| Celecoxib | Celecoxib | 49 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Meloxicam | Meloxicam | 48 | suppressed |
| Tradjenta | Linagliptin | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | 24 |
| Methenamine Hippurate | Methenamine Hippurate | 46 | suppressed |
| Methimazole | Methimazole | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 44 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 26 |
| Mirabegron Er | Mirabegron | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Cilostazol | Cilostazol | 39 | suppressed |
| Famotidine | Famotidine | 38 | 13 |
| Morphine Sulfate | Morphine Sulfate | 38 | 28 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 26 |
| Cephalexin | Cephalexin | 36 | 21 |
| Gemtesa | Vibegron | 36 | suppressed |
| Amantadine | Amantadine Hcl | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 12 |
| Folic Acid | Folic Acid | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 25 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 34 | 34 |
| Rexulti | Brexpiprazole | 34 | suppressed |
| Metolazone | Metolazone | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Calcitriol | Calcitriol | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | 11 |
| Cefuroxime | Cefuroxime Axetil | 27 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Valsartan | Valsartan | 27 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 26 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 16 |
| Silodosin | Silodosin | 26 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 16 |
| Glipizide | Glipizide | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Ssd | Silver Sulfadiazine | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Probenecid | Probenecid | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,108.72 · 42 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, FARXIGA, GARDASIL 9, INSPIRE, JARDIANCE, KESIMPTA, MOUNJARO, NUEDEXTA, Ozempic, REXULTI, TRELEGY ELLIPTA, UBRELVY, WATCHMAN FLX, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error